Boston Scientific Closes $615M Deal for Apollo Endosurgery

Boston Scientific has closed the acquisition of Apollo Endosurgery, a company focused on design, development, and commercialization of next-gen, less invasive medical devices for gastrointestinal therapeutic endoscopy and endobariatrics.
 
The deal to acquire Apollo Endosurgery was first announced in November 2022. The deal was valued for a cash price of $10 per share, representing an enterprise value of about $615 million.
 
“The close of this acquisition is an exciting step forward in our ability to provide our customers and their patients with a more comprehensive suite of endoluminal surgery (ELS) and endobariatric solutions,” Mike Jones, senior VP and president, Endoscopy, Boston Scientific, said in press release. “We look forward to welcoming new talent to our Endoscopy team that will help advance innovation for physicians to improve patient care.” 
 
Adding Apollo Endosurgery’s devices will build on Boston Scientific’s current ELS portfolio and capabilities, particularly in closure and suturing, and begin a measured entry into the endobariatric market.